FR14C0075I1 - MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Google Patents

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Info

Publication number: FR14C0075I1
Authority: FR; France
Prior art keywords: receptor antagonists; acetylcholine receptor; muscarinic acetylcholine; muscarinic; antagonists
Prior art date: 2004-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-27

Filing date

2014-10-02

Publication date

2014-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0075(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-02 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2014-11-21 Publication of FR14C0075I1 publication Critical patent/FR14C0075I1/en

2015-05-22 Application granted granted Critical

2015-05-22 Publication of FR14C0075I2 publication Critical patent/FR14C0075I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

FR14C0075C 2004-04-27 2014-10-02 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS Active FR14C0075I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56562304P	2004-04-27	2004-04-27
PCT/US2005/014386 WO2005104745A2 (en)	2004-04-27	2005-04-27	Muscarinic acetylcholine receptor antagonists

Publications (2)

Publication Number	Publication Date
FR14C0075I1 true FR14C0075I1 (en)	2014-11-21
FR14C0075I2 FR14C0075I2 (en)	2015-05-22

Family

ID=35242158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0075C Active FR14C0075I2 (en)	2004-04-27	2014-10-02	MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Country Status (38)

Country	Link
US (9)	US7498440B2 (en)
EP (3)	EP2570128B1 (en)
JP (2)	JP5014121B2 (en)
KR (2)	KR101152032B1 (en)
CN (2)	CN1976701A (en)
AP (1)	AP2213A (en)
AR (1)	AR050902A1 (en)
AU (1)	AU2005237576B2 (en)
BE (1)	BE2014C063I2 (en)
BR (1)	BRPI0510170B8 (en)
CA (2)	CA2755954C (en)
CY (3)	CY1113196T1 (en)
DK (2)	DK1740177T3 (en)
EA (2)	EA021994B1 (en)
EC (1)	ECSP066940A (en)
ES (2)	ES2392848T4 (en)
FR (1)	FR14C0075I2 (en)
HR (2)	HRP20120832T1 (en)
HU (2)	HUE031304T2 (en)
IL (1)	IL178152A (en)
LT (1)	LT2570128T (en)
LU (1)	LU92565I2 (en)
MA (1)	MA28631B1 (en)
MX (1)	MXPA06012405A (en)
MY (1)	MY144753A (en)
NL (1)	NL300694I1 (en)
NO (3)	NO338959B1 (en)
NZ (1)	NZ549997A (en)
PE (1)	PE20060259A1 (en)
PL (2)	PL2570128T3 (en)
PT (2)	PT2570128T (en)
SG (1)	SG186597A1 (en)
SI (2)	SI2570128T1 (en)
TW (1)	TWI363759B (en)
UA (1)	UA95768C2 (en)
UY (1)	UY28871A1 (en)
WO (1)	WO2005104745A2 (en)
ZA (1)	ZA200608565B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20050250A1 (en) *	2003-07-17	2005-04-08	Glaxo Group Ltd	ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
JP2007509061A (en) *	2003-10-17	2007-04-12	グラクソ　グループ　リミテッド	Muscarinic acetylcholine receptor antagonist
AR046225A1 (en) *	2003-11-04	2005-11-30	Glaxo Group Ltd	COMPOSITE OF 8-AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS THAT UNDERSTAND IT AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
JP2007528420A (en) *	2004-03-11	2007-10-11	グラクソ　グループ　リミテッド	Novel M3 muscarinic acetylcholine receptor antagonist
US20070185148A1 (en) *	2004-03-17	2007-08-09	Glaxo Group Limited	M3 muscarinic acetylchoine receptor antagonists
EP1725564A4 (en) *	2004-03-17	2007-09-12	Glaxo Group Ltd	M3 muscarinic acetylcholine receptor antagonists
DE602005009158D1 (en) *	2004-04-05	2008-10-02	Samaritan Pharmaceuticals Inc	ANTI-HIV CHINUKLIDINVERBINDUNGEN
AR050902A1 (en)	2004-04-27	2006-12-06	Glaxo Group Ltd	QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
WO2005112644A2 (en) *	2004-05-13	2005-12-01	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
EP1957075A4 (en) *	2004-11-15	2009-11-18	Glaxo Group Ltd	Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (en) *	2005-08-02	2007-02-08	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) *	2005-08-18	2007-02-22	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
EA200801997A1 (en)	2006-04-20	2009-04-28	Глаксо Груп Лимитед	NEW CONNECTIONS
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
SI2046787T1 (en)	2006-08-01	2011-07-29	Glaxo Group Ltd	PYRAZOLO?á3,4-B?åPYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
PE20081889A1 (en)	2007-03-23	2009-03-05	Smithkline Beecham Corp	INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
UY31637A1 (en)	2008-02-06	2009-08-03		DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
TW200946526A (en)	2008-02-06	2009-11-16	Glaxo Group Ltd	Dual pharmacophores-PDE4-muscarinic antagonistics
UY31636A1 (en)	2008-02-06	2009-08-03		DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
US8163743B2 (en)	2008-06-05	2012-04-24	GlaxoGroupLimited	4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
US8765743B2 (en)	2008-06-05	2014-07-01	Glaxosmithkline Intellectual Property Development Limited	Compounds
WO2010094643A1 (en)	2009-02-17	2010-08-26	Glaxo Group Limited	Quinoline derivatives and their uses for rhinitis and urticaria
SI2400950T1 (en)	2009-02-26	2019-09-30	Glaxo Group Limited	Pharmaceutical formulations comprising 4-((1 r)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
US8524751B2 (en)	2009-03-09	2013-09-03	GlaxoSmithKline Intellecutual Property Development	4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
EP2406249A1 (en)	2009-03-10	2012-01-18	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
US20120058984A1 (en)	2009-03-17	2012-03-08	Catherine Mary Alder	Pyrimidine derivatives used as itk inhibitors
WO2010125082A1 (en)	2009-04-30	2010-11-04	Glaxo Group Limited	Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011029896A1 (en)	2009-09-11	2011-03-17	Glaxo Group Limited	Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
JP2013512880A (en)	2009-12-03	2013-04-18	グラクソグループリミテッド	Indazole derivatives as PI3-kinase inhibitors
EP2507223A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507226A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Novel compounds
ES2655083T3 (en) *	2010-01-28	2018-02-16	Theron Pharmaceuticals, Inc.	Derivatives of 7-azoniabicyclo [2.2.1] heptane, production methods, and pharmaceutical uses of these
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
AU2011269238A1 (en) *	2010-06-22	2013-01-10	Chiesi Farmaceutici S.P.A.	Dry powder formulation comprising an antimuscarinic drug
DK2614058T3 (en)	2010-09-08	2015-09-28	Glaxosmithkline Ip Dev Ltd	Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
KR20140041699A (en) *	2011-06-08	2014-04-04	글락소 그룹 리미티드	Combination comprising umeclidinium and corticosteroids
US20140116434A1 (en)	2011-06-08	2014-05-01	Glaxo Group Limited	Dry Powder Inhaler Compositions
EP2836204B1 (en)	2012-04-13	2020-07-08	GlaxoSmithKline Intellectual Property Development Limited	Aggregate particles
RU2502743C1 (en) *	2012-08-03	2013-12-27	Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России)	Synthetic antigen having ability to fix autoantibodies to muscarine m2-receptor
CN104619706B (en) *	2012-08-15	2017-06-20	葛兰素集团有限公司	chemical method
GB201222679D0 (en) *	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
CA2921621C (en)	2013-07-13	2018-08-28	Beijing Fswelcome Technology Development Co., Ltd	Quinine compounds, and optical isomers, preparation method and medical use thereof
BR112016001696A2 (en)	2013-07-30	2017-08-01	Glaxosmithkline Ip Dev Ltd	topical compositions for the treatment of excessive sweating and methods of using these
AU2014336250A1 (en)	2013-10-17	2016-04-14	Glaxosmithkline Intellectual Property Development Limited	PI3K inhibitor for treatment of respiratory disease
RU2016112266A (en)	2013-10-17	2017-11-20	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	PI3K inhibitor for the treatment of respiratory disease
AU2015260841A1 (en)	2014-05-12	2016-12-01	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions comprising danirixin for treating infectious diseases
ES2775606T3 (en)	2014-05-28	2020-07-27	Glaxosmithkline Ip Dev Ltd	Fluticasone furoate in the treatment of COPD
ES2751698T3 (en)	2014-11-03	2020-04-01	Olon Spa	Procedure for the preparation of 1- (2-halogen-ethyl) -4-piperidine-carboxylic acid ethyl ester
KR101613245B1 (en)	2015-04-27	2016-04-18	주식회사 대웅제약	Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
CN105461710A (en) *	2015-10-23	2016-04-06	安徽德信佳生物医药有限公司	Preparation method of umeclidinium bromide
CN108473437B (en) *	2016-01-08	2022-03-25	西伦制药公司	Dry powder inhaler compositions of 7-azabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN107200734B (en) *	2016-03-18	2019-12-24	益方生物科技（上海）有限公司	Quinuclidine derivative and preparation method and application thereof
EP3248970A1 (en)	2016-05-27	2017-11-29	Zentiva K.S.	Forms of umeclidinium bromide
US20190161480A1 (en)	2016-08-08	2019-05-30	Glaxosmithkline Intellectual Property Development Limited	Chemical Compounds
PT109740B (en) *	2016-11-14	2020-07-30	Hovione Farmaciencia Sa	PROCESS FOR THE PREPARATION OF UMECLIDINUM BROMIDE
WO2018163212A1 (en) *	2017-03-08	2018-09-13	Gbr Laboratories Pvt. Ltd	A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
IT201700058796A1 (en) *	2017-05-30	2018-11-30	Olon Spa	Procedure for the preparation of a new intermediate of synthesis of umeclidinium.
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CA3080656A1 (en)	2017-10-30	2019-05-09	Baxalta GmbH	Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (en) *	2018-06-04	2020-12-25	成都伊诺达博医药科技有限公司	Method for synthesizing umeclidinium bromide
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
PT115583B (en)	2019-06-17	2022-05-02	Hovione Farm S A	CONTINUOUS PROCESS FOR THE PREPARATION OF ANTICHOLINERGIC DRUGS
CN113387923A (en) *	2020-03-13	2021-09-14	诺华股份有限公司	Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same
BR112022019245A2 (en)	2020-03-26	2022-11-16	Glaxosmithkline Ip Dev Ltd	CATHEPSIN INHIBITORS TO PREVENT OR TREAT VIRAL INFECTIONS
CN111484445B (en) *	2020-04-21	2021-05-18	广东莱佛士制药技术有限公司	Method for separating and purifying intermediate of high-purity Wumei ammonium bromide
JP2023523453A (en)	2020-04-26	2023-06-05	ベイジン・ショウバイ・ファーマシューティカル・カンパニー・リミテッド	M receptor antagonist crystal, preparation method and its application
KR20230093251A (en)	2020-09-10	2023-06-27	프리시릭스 엔.브이.	Antibody fragment against FAP
CN112479983B (en) *	2020-11-25	2022-07-12	江苏豪森药业集团有限公司	Wumei ammonium bromide intermediate and preparation method thereof
PT117440B (en)	2021-09-03	2024-04-26	Hovione Farm S A	PROCESS FOR THE PREPARATION OF CHLOROAQUIL SUBSTITUTED CYCLIC AMINES
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
KR20250034289A (en)	2022-05-02	2025-03-11	프리시릭스 엔.브이.	Pre-targeting
WO2024251812A1 (en)	2023-06-07	2024-12-12	Pharmazell Gmbh	A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2800481A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (en) *	1967-06-08	1972-04-25	Siemens Ag	Method for converting voltages into digital values and device for carrying out the method
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1230087A (en)	1967-08-17	1971-04-28
GB1381872A (en)	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
CY1492A (en)	1981-07-08	1990-02-16	Draco Ab	Powder inhalator
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
FI79651C (en)	1982-10-08	1990-02-12	Glaxo Group Ltd	DOSERING PROCEDURE FOR MEDICINE.
FR2585563B1 (en)	1985-07-30	1993-11-12	Glaxo Group Ltd	DEVICE FOR ADMINISTERING MEDICINES TO PATIENTS
IT1204826B (en)	1986-03-04	1989-03-10	Chiesi Farma Spa	INHALATION PHARMACEUTICAL COMPOSITIONS
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5780466A (en) *	1995-01-30	1998-07-14	Sanofi	Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) *	1996-12-02	1998-06-11	Georgetown University	Tropane derivatives and method for their synthesis
US6248752B1 (en) *	1998-02-27	2001-06-19	Charles Duane Smith	Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) *	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (en) *	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
UA75626C2 (en) *	2000-12-28	2006-05-15	Almirall Prodesfarma Ag	Quinuclidine derivatives and medicinal compositions containing the same
KR20050030169A (en) *	2001-10-17	2005-03-29	유씨비 소시에떼아노님	Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
JP2005510523A (en) *	2001-11-09	2005-04-21	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	Azabicyclic phenyl fused heterocyclic compounds and use of the compounds as α7NACHR ligands
UA76571C2 (en) *	2001-12-20	2006-08-15		Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
US6696462B2 (en)	2002-01-31	2004-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (en)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	NEW DERIVATIVES OF PIRROLIDINIO.
ES2204295B1 (en) *	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
PE20040892A1 (en)	2002-08-06	2004-11-19	Glaxo Group Ltd	ACETYLCHOLINE MUSCARINE M3 RECEPTOR ANTAGONISTS
JP2006522161A (en)	2003-04-07	2006-09-28	グラクソ　グループ　リミテッド	M3 muscarinic acetylcholine receptor antagonist
PE20050250A1 (en)	2003-07-17	2005-04-08	Glaxo Group Ltd	ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
PE20050327A1 (en)	2003-07-17	2005-06-08	Glaxo Group Ltd	DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANE AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE RECEPTORS
AR048573A1 (en)	2003-07-17	2006-05-10	Glaxo Group Ltd	COMPOSITE OF 8-AZONIABICICLO [3.2.1] OCTANO REPLACED IN POSITION 3, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
MXPA06004244A (en)	2003-10-14	2006-06-28	Glaxo Group Ltd	Muscarinic acetycholine receptor antagonists.
JP2007509061A (en)	2003-10-17	2007-04-12	グラクソ　グループ　リミテッド	Muscarinic acetylcholine receptor antagonist
AR046225A1 (en)	2003-11-04	2005-11-30	Glaxo Group Ltd	COMPOSITE OF 8-AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS THAT UNDERSTAND IT AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
CA2543858C (en) *	2003-11-21	2014-04-15	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
UY28646A1 (en)	2003-12-03	2005-06-30	Glaxo Group Ltd	NEW ANTAGONISTS OF THE M3 ACETILCOLINE MUSCARINIC RECEPTOR
UY28645A1 (en)	2003-12-03	2005-06-30	Glaxo Group Ltd	NEW ANTAGONISTS OF THE M3 ACETILCOLINE MUSCARINIC RECEPTOR
TW200534855A (en)	2004-01-13	2005-11-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
JP2007528420A (en)	2004-03-11	2007-10-11	グラクソ　グループ　リミテッド	Novel M3 muscarinic acetylcholine receptor antagonist
EP1751089A4 (en)	2004-03-11	2010-03-10	Glaxo Group Ltd	Novel m3 muscarinic acetylcholine receptor antagonists
WO2005094834A1 (en)	2004-03-17	2005-10-13	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
JP2007529514A (en)	2004-03-17	2007-10-25	グラクソ　グループ　リミテッド	M3 muscarinic acetylcholine receptor antagonist
EP1725564A4 (en)	2004-03-17	2007-09-12	Glaxo Group Ltd	M3 muscarinic acetylcholine receptor antagonists
US20070185148A1 (en)	2004-03-17	2007-08-09	Glaxo Group Limited	M3 muscarinic acetylchoine receptor antagonists
EP1732923A2 (en)	2004-04-07	2006-12-20	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
AR050902A1 (en) *	2004-04-27	2006-12-06	Glaxo Group Ltd	QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
WO2005112644A2 (en)	2004-05-13	2005-12-01	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
US7579345B2 (en)	2004-05-28	2009-08-25	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
JP2008505118A (en)	2004-06-30	2008-02-21	グラクソ　グループ　リミテッド	Muscarinic acetylcholine receptor antagonist
WO2006017768A2 (en)	2004-08-05	2006-02-16	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
JP2008509158A (en)	2004-08-06	2008-03-27	グラクソグループリミテッド	Muscarinic acetylcholine receptor antagonist
JP2008518939A (en)	2004-10-29	2008-06-05	グラクソグループリミテッド	Muscarinic acetylcholine receptor antagonist
EP1957075A4 (en)	2004-11-15	2009-11-18	Glaxo Group Ltd	Novel m3 muscarinic acetylcholine receptor antagonists
JP2008520573A (en)	2004-11-15	2008-06-19	グラクソグループリミテッド	Novel M3 muscarinic acetylcholine receptor antagonist
PE20061162A1 (en)	2004-12-06	2006-10-14	Smithkline Beecham Corp	COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
PE20060826A1 (en)	2004-12-06	2006-10-08	Smithkline Beecham Corp	OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
WO2006065788A2 (en)	2004-12-13	2006-06-22	Glaxo Group Limited	Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en)	2004-12-13	2006-06-22	Glaxo Group Limited	Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en)	2005-07-28	2007-02-15	Glaxo Group Limited	Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en)	2005-07-28	2007-02-15	Glaxo Group Limited	Novel m3 muscarinic acetycholine receptor antagonists
WO2007016639A2 (en)	2005-08-02	2007-02-08	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
EP1937230A4 (en)	2005-08-02	2009-08-26	Glaxo Group Ltd	M3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en)	2005-08-18	2007-02-22	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents

2005
- 2005-04-25 AR ARP050101627A patent/AR050902A1/en active IP Right Grant
- 2005-04-25 PE PE2005000457A patent/PE20060259A1/en active IP Right Grant
- 2005-04-25 MY MYPI20051806A patent/MY144753A/en unknown
- 2005-04-25 UY UY28871A patent/UY28871A1/en not_active Application Discontinuation
- 2005-04-25 TW TW094113034A patent/TWI363759B/en active
- 2005-04-27 DK DK05746609.6T patent/DK1740177T3/en active
- 2005-04-27 EA EA201100019A patent/EA021994B1/en not_active IP Right Cessation
- 2005-04-27 EA EA200601991A patent/EA015033B1/en not_active IP Right Cessation
- 2005-04-27 PL PL12170402T patent/PL2570128T3/en unknown
- 2005-04-27 SI SI200532099A patent/SI2570128T1/en unknown
- 2005-04-27 PL PL05746609T patent/PL1740177T3/en unknown
- 2005-04-27 HU HUE12170402A patent/HUE031304T2/en unknown
- 2005-04-27 CA CA2755954A patent/CA2755954C/en not_active Expired - Lifetime
- 2005-04-27 CN CNA2005800215360A patent/CN1976701A/en active Pending
- 2005-04-27 NZ NZ549997A patent/NZ549997A/en not_active IP Right Cessation
- 2005-04-27 BR BRPI0510170A patent/BRPI0510170B8/en active IP Right Grant
- 2005-04-27 ES ES05746609.6T patent/ES2392848T4/en not_active Expired - Lifetime
- 2005-04-27 EP EP12170402.7A patent/EP2570128B1/en not_active Expired - Lifetime
- 2005-04-27 PT PT121704027T patent/PT2570128T/en unknown
- 2005-04-27 CN CN2010105580787A patent/CN102040602A/en active Pending
- 2005-04-27 SI SI200531605T patent/SI1740177T1/en unknown
- 2005-04-27 JP JP2007510915A patent/JP5014121B2/en not_active Expired - Lifetime
- 2005-04-27 AU AU2005237576A patent/AU2005237576B2/en active Active
- 2005-04-27 CA CA2564742A patent/CA2564742C/en not_active Expired - Lifetime
- 2005-04-27 KR KR1020117001909A patent/KR101152032B1/en not_active Expired - Lifetime
- 2005-04-27 AP AP2006003746A patent/AP2213A/en active
- 2005-04-27 ES ES12170402.7T patent/ES2600405T3/en not_active Expired - Lifetime
- 2005-04-27 DK DK12170402.7T patent/DK2570128T3/en active
- 2005-04-27 SG SG2012087052A patent/SG186597A1/en unknown
- 2005-04-27 MX MXPA06012405A patent/MXPA06012405A/en active IP Right Grant
- 2005-04-27 EP EP16177012.8A patent/EP3111936A1/en not_active Withdrawn
- 2005-04-27 KR KR1020067022276A patent/KR101037026B1/en not_active Expired - Lifetime
- 2005-04-27 LT LTEP12170402.7T patent/LT2570128T/en unknown
- 2005-04-27 US US11/568,330 patent/US7498440B2/en not_active Expired - Lifetime
- 2005-04-27 UA UAA200611253A patent/UA95768C2/en unknown
- 2005-04-27 EP EP05746609A patent/EP1740177B1/en not_active Expired - Lifetime
- 2005-04-27 PT PT05746609T patent/PT1740177E/en unknown
- 2005-04-27 WO PCT/US2005/014386 patent/WO2005104745A2/en not_active Ceased
- 2005-04-27 HR HRP20120832TT patent/HRP20120832T1/en unknown
2006
- 2006-09-18 IL IL178152A patent/IL178152A/en active Protection Beyond IP Right Term
- 2006-10-13 ZA ZA2006/08565A patent/ZA200608565B/en unknown
- 2006-10-20 EC EC2006006940A patent/ECSP066940A/en unknown
- 2006-10-31 MA MA29426A patent/MA28631B1/en unknown
- 2006-11-24 NO NO20065417A patent/NO338959B1/en active Protection Beyond IP Right Term
2007
- 2007-07-09 US US11/774,867 patent/US7488827B2/en active Active
2009
- 2009-01-14 US US12/353,436 patent/US8183257B2/en not_active Expired - Lifetime
2012
- 2012-02-22 US US13/401,890 patent/US8309572B2/en not_active Expired - Lifetime
- 2012-04-13 JP JP2012092339A patent/JP5398871B2/en not_active Expired - Lifetime
- 2012-09-26 US US13/627,007 patent/US8575347B2/en not_active Expired - Fee Related
- 2012-10-17 CY CY20121100965T patent/CY1113196T1/en unknown
2013
- 2013-10-14 US US14/052,816 patent/US8853404B2/en not_active Expired - Lifetime
2014
- 2014-09-04 US US14/476,940 patent/US9045469B2/en not_active Expired - Lifetime
- 2014-09-26 HU HUS1400053C patent/HUS1400053I1/en unknown
- 2014-10-02 BE BE2014C063C patent/BE2014C063I2/fr unknown
- 2014-10-02 FR FR14C0075C patent/FR14C0075I2/en active Active
- 2014-10-02 NL NL300694C patent/NL300694I1/nl unknown
- 2014-10-02 LU LU92565C patent/LU92565I2/en unknown
- 2014-10-03 CY CY2014043C patent/CY2014043I2/en unknown
2015
- 2015-05-08 US US14/707,543 patent/US9144571B2/en not_active Expired - Lifetime
- 2015-09-10 US US14/849,775 patent/US20160002220A1/en not_active Abandoned
2016
- 2016-10-10 CY CY20161101008T patent/CY1118082T1/en unknown
- 2016-10-25 HR HRP20161385TT patent/HRP20161385T1/en unknown
2017
- 2017-05-04 NO NO2017018C patent/NO2017018I2/en unknown
- 2017-05-04 NO NO2017017C patent/NO2017017I1/en unknown

Also Published As

Publication number	Publication date
HUE031304T2 (en)	2017-07-28
LU92565I2 (en)	2014-12-02
CA2755954A1 (en)	2005-11-10
ES2392848T3 (en)	2012-12-14
KR20070015412A (en)	2007-02-02
AP2006003746A0 (en)	2006-10-31
CN102040602A (en)	2011-05-04
ES2600405T3 (en)	2017-02-08
FR14C0075I2 (en)	2015-05-22
NO20065417L (en)	2006-12-29
DK2570128T3 (en)	2016-11-07
MY144753A (en)	2011-10-31
CY2014043I1 (en)	2015-12-09
LU92565I9 (en)	2019-01-17
JP2007534769A (en)	2007-11-29
ECSP066940A (en)	2006-12-20
US8183257B2 (en)	2012-05-22
CA2755954C (en)	2014-02-18
KR101037026B1 (en)	2011-05-25
NO2017017I1 (en)	2017-05-04
CA2564742C (en)	2012-01-10
MA28631B1 (en)	2007-06-01
CY1118082T1 (en)	2017-06-28
ZA200608565B (en)	2019-12-18
JP5014121B2 (en)	2012-08-29
HRP20120832T1 (en)	2012-11-30
EP1740177A2 (en)	2007-01-10
HUS1400053I1 (en)	2017-07-28
US9045469B2 (en)	2015-06-02
NL300694I2 (en)	2015-12-29
NO338959B1 (en)	2016-11-07
SG186597A1 (en)	2013-01-30
US8309572B2 (en)	2012-11-13
EA201100019A1 (en)	2011-12-30
BRPI0510170B8 (en)	2021-05-25
EP2570128B1 (en)	2016-08-10
NL300694I1 (en)	2015-12-29
PE20060259A1 (en)	2006-03-25
US8575347B2 (en)	2013-11-05
TW200605887A (en)	2006-02-16
ES2392848T4 (en)	2014-10-01
BE2014C063I2 (en)	2024-08-08
EP2570128A1 (en)	2013-03-20
US7498440B2 (en)	2009-03-03
CY2014043I2 (en)	2015-12-09
US20070249664A1 (en)	2007-10-25
US20140080863A1 (en)	2014-03-20
EP1740177B1 (en)	2012-08-08
AR050902A1 (en)	2006-12-06
US20070185155A1 (en)	2007-08-09
NO2017018I2 (en)	2018-05-14
BRPI0510170B1 (en)	2018-12-18
MXPA06012405A (en)	2007-01-17
PT2570128T (en)	2016-10-07
HRP20161385T1 (en)	2016-12-02
NZ549997A (en)	2010-10-29
KR20110010841A (en)	2011-02-07
US20140371264A1 (en)	2014-12-18
US20090124653A1 (en)	2009-05-14
DK1740177T3 (en)	2012-10-29
UY28871A1 (en)	2005-11-30
AU2005237576B2 (en)	2012-01-12
CY1113196T1 (en)	2015-12-09
EA021994B1 (en)	2015-10-30
AU2005237576A1 (en)	2005-11-10
EP1740177A4 (en)	2010-05-05
AP2213A (en)	2011-03-01
LT2570128T (en)	2016-10-10
UA95768C2 (en)	2011-09-12
EA015033B1 (en)	2011-04-29
US20130030015A1 (en)	2013-01-31
WO2005104745A3 (en)	2006-08-03
US20160002220A1 (en)	2016-01-07
JP2012162559A (en)	2012-08-30
EA200601991A1 (en)	2007-02-27
NO2017018I1 (en)	2017-05-04
PT1740177E (en)	2012-11-02
US20120157491A1 (en)	2012-06-21
SI2570128T1 (en)	2016-11-30
EP3111936A1 (en)	2017-01-04
US9144571B2 (en)	2015-09-29
US7488827B2 (en)	2009-02-10
WO2005104745A2 (en)	2005-11-10
PL2570128T3 (en)	2017-09-29
KR101152032B1 (en)	2012-06-11
PL1740177T3 (en)	2012-12-31
CA2564742A1 (en)	2005-11-10
SI1740177T1 (en)	2012-12-31
JP5398871B2 (en)	2014-01-29
IL178152A (en)	2011-05-31
TWI363759B (en)	2012-05-11
BRPI0510170A (en)	2007-10-02
CN1976701A (en)	2007-06-06
US20150238470A1 (en)	2015-08-27
HK1102423A1 (en)	2007-11-23
US8853404B2 (en)	2014-10-07
IL178152A0 (en)	2006-12-31

Publication	Publication Date	Title
FR14C0075I2 (en)	2015-05-22	MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
IL188112A0 (en)	2008-03-20	Muscarinic acetylcholine receptor antagonists
DK1682142T3 (en)	2012-10-15	M3-muscarinic acetylcholine receptor antagonists
EP1725240A4 (en)	2009-03-25	Muscarinic acetylcholine receptor antagonists
IS8522A (en)	2006-06-26	New M3 muscarinic acetylcholine receptor antagonists
IS8515A (en)	2006-06-19	New M3 muscarinic acetylcholine receptor antagonists
MA28363A1 (en)	2006-12-01	ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE RECEPTORS
EP1648460A4 (en)	2009-04-01	Muscarinic acetylcholine receptor antagonists
EP1725236A4 (en)	2009-05-13	Novel m3 muscarinic acetylcholine receptor antagonists
IL172912A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
IL172911A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
EP1937068A4 (en)	2010-08-04	Muscarinic acetylcholine receptor antagonists
EP1957075A4 (en)	2009-11-18	Novel m3 muscarinic acetylcholine receptor antagonists
EP1824483A4 (en)	2009-11-04	Muscarinic acetylcholine receptor antagonists
EP1749012A4 (en)	2009-07-29	Muscarinic acetylcholine receptor antagonists
EP1827439A4 (en)	2009-11-18	Novel m3 muscarinic acetylcholine receptor antagonists
IL174846A0 (en)	2006-08-20	Muscarinic acetylcholine receptor antagonists
EP1725241A4 (en)	2009-03-25	M3 muscarinic acetylcholine receptor antagonists
EP1747219A4 (en)	2010-05-26	Muscarinic acetylcholine receptor antagonists field of the invention
EP1725564A4 (en)	2007-09-12	M3 muscarinic acetylcholine receptor antagonists
EP1765339A4 (en)	2009-09-02	Muscarinic acetylcholine receptor antagonists
EP1781104A4 (en)	2008-05-21	Muscarinic acetylcholine receptor antagonists
EP1781103A4 (en)	2008-05-14	Muscarinic acetylcholine receptor antagonists
EP1751089A4 (en)	2010-03-10	Novel m3 muscarinic acetylcholine receptor antagonists